{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-022613","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.259900+00:00","generated_at":"2026-06-04T19:15:46.008928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HeartSciences Q3 cash $7.1M; licenses AI-ECG from Mount Sinai; FDA 510(k) path","bullets":["No significant revenue in Q3 FY2024; cash $7.1M, shareholders' equity $8.6M as of Jan 31, 2024.","Raised $9.2M net from stock sales and converted $1.1M debt to equity during quarter.","Licensed AI-ECG algorithms and IP from Icahn School of Medicine at Mount Sinai; Mount Sinai became largest shareholder.","FDA pathway changed to 510(k) for MyoVista device; targeting FDA clearance around calendar year-end 2024.","Peer-reviewed study showed MyoVista AI-ECG outperformed standard screening for heart disease in diabetic patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-022613","json":"https://secwatch.observer/filing/0001213900-24-022613.json","markdown":"https://secwatch.observer/filing/0001213900-24-022613.md","text":"https://secwatch.observer/filing/0001213900-24-022613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/0001213900-24-022613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/ea0201847-8k_hearttest.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:15:46.008928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f223d6366939701d497ee0d7c79ce5838622524","claim":"HeartSciences Inc. reported third quarter fiscal 2024 ended January 31, 2024 results: revenue There were no significant revenues in the third quarter fiscal 2024..","evidence_excerpt":"HeartSciences Reports Third Quarter Fiscal 2024 Financial Results Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc . d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/0001213900-24-022613-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter fiscal 2024 ended January 31, 2024"},{"label":"Revenue","value":"There were no significant revenues in the third quarter fiscal 2024."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}